DRUG DEVELOPMENT FOR TOXOPLASMOSIS ASSOCIATED WITH AIDS

治疗与艾滋病相关的弓形虫病的药物开发

基本信息

批准号：
2867256
负责人：
FAUSTO G ARAUJO
金额：
--
依托单位：
PALO ALTO MEDICAL FOUNDATION RES INST
依托单位国家：
美国
项目类别：
财政年份：
1993
资助国家：
美国
起止时间：
1993-09-30 至 1999-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2867256
关键词：
DRUG DEVELOPMENT TOXOPLASMOSIS ASSOCIATED AIDS

项目摘要

The Developmental Therapeutics Branch, Basic Research and Development Program, Division of AIDS, as part of its mission, facilitates research efforts related to the discovery and development of new therapies for the treatment of HIV infection and the opportunistic infections (OIs) associated with AIDS. Between 10 and 40 % of AIDS patients in the United States are at risk of developing toxoplasmic encephalitis (TE) through reactivation of latent Toxoplasma infections. Current therapies for TE have proven toxic, expensive, or only partially effective. Development of new, more efficacious therapeutic agents is of utmost importance, yet it has been limited by l) the difficulty of preclinical testing of potential therapies 2) the general lack of pharmaceutical industry research and development in this area, and 3) the relative lack of information on the biological and immunologic processes that control chronic and latent Toxoplasma infections. This contract will provide a critical resource for expeditious evaluations of new therapies for toxoplasmic encephalitis and the continued development of in vivo and in vitro models for toxoplasmic encephalitis and latent infection. This project will complement other activities in the Division's strategy to stimulate OI drug discovery and development by providing in vivo and in vitro test systems for TE that are not readily available to the scientific community. Such a resource will allow NIAID to provide critical support for investigator-initiated drug discovery for TE, to stimulate private sector sponsorship of new drugs, to perform comparative studies of drugs and drug combinations to be used in multiple OI prophylaxis studies, and contribute essential information for the design of clinical studies.

发展治疗学分部，基础研究与开发艾滋病司的计划作为其使命的一部分，促进研究与发现和开发新疗法有关的努力 HIV 感染和机会性感染 (OIs) 的治疗与艾滋病有关。美国 10% 到 40% 的艾滋病患者各州有患弓形虫脑炎 (TE) 的风险潜伏弓形虫感染的重新激活。目前 TE 的治疗方法已被证明有毒、昂贵或仅部分有效。发展新的、更有效的治疗药物至关重要，但受到以下因素的限制：l) 潜在的临床前测试的难度 2）医药行业普遍缺乏研究和治疗 3）该领域的信息相对缺乏控制慢性和潜伏的生物和免疫过程弓形虫感染。该合同将为快速评估提供关键资源弓形虫脑炎的新疗法和持续的弓形虫脑炎体内和体外模型的开发和潜伏感染。该项目将补充该领域的其他活动该部门刺激 OI 药物发现和开发的战略为TE提供不容易的体内和体外测试系统可供科学界使用。这样的资源将允许 NIAID 为研究者发起的药物发现提供关键支持 TE，刺激私营部门对新药的赞助，执行多种药物和药物组合的比较研究成骨不全预防研究，并为以下方面提供重要信息：临床研究的设计。